Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis

Summary

This is a two-part, multi-center, randomized, double-blind, placebo-controlled, parallel-group study in patients with hip OA. Approximately 70 patients will be enrolled in Part I and approximately 440 patients will be enrolled in Part II of the study. In each part, patients will be randomized to one of two treatment groups (1:1) and treated with a single IA injection of either 32 mg FX006 or normal saline.

Timeline

Start

2018-12-12

Primary completion

2019-08-07

Completion

2019-08-07

Drugs

Indications